Catherine Skari

Renzo Galanello Fellowship Programme 2020

Read More »

Thalassaemia Month of Banyumas 2019 -“Banyumas Goes to Zero Growth of Thalassaemia 2023”

Written by Dinar Faiza (edited)   The Indonesian Thalassemia Foundation of Banyumas and the Banyumas District Government organised and launched,…

Read More »

The Emirates Thalassaemia Society launches the 12th edition of the ”What is Thalassaemia?”competition

  The Emirates Thalassemia Society (ETS), a prominent TIF’s Member, in collaboration with the United Arab Emirates’ Ministry of Education,…

Read More »

Global Blood Therapeutics & Syros Pharma team up on novel therapies for β-thalassaemia & SCD

Global Blood Therapeutics (GBT) and Syros Pharma announced yesterday their partnership to discover, develop and commercialize novel therapies for SickleCell…

Read More »

Delegation Visit to Italy – 15 December 2019

A Symposium on the ‘Diagnosis and Treatment of Chronic Liver Disease and Disturbances in Heart Rhythm in Haemoglobinopathies’ was organised…

Read More »

TIF organises the‘’1st International Informational Forum on New & Innovative Therapies for Haemoglobinopathies’’_12 December 2019

  In light of the rapid scientific developments in the field of thalassaemia and Sickle Cell Disease (SCD) – new…

Read More »

TIF by the side of thalassaemia patients in Syria

  The World Health Organisation (WHO) has contacted the Thalassaemia International Federation (TIF) to request the provision of its expertise…

Read More »

TIF will coordinate efforts for patients’ information on Reblozyl in 62 countries

A new and encouraging chapter is finally opening up for patients with thalassaemia, following the recent approval of the US…

Read More »

ASH ANNUAL MEETING | 7-10 December 2019

  Celgene Corporation, Acceleron Pharma, Sangamo Therapeutics & Agios Pharmaceuticals are expected to present new and updated data on the…

Read More »

Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major obtained approval by the EMA

  The European Medicines Agency’s (EMA) has recently granted marketing authorisation for the medicinal product ”Deferasirox Mylan”, intended for the treatment of…

Read More »